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The range of S-selectivity of linear and cyclic analogues of enkephalin in rat brain was found to be: [D-Pe?, 
L-Pins] enkephalin (DPLPE) > [D-Pdnz, D-Pens] enkephalin (DPDPE) > [D-Thr*, Leuq enkephalyl-Thr6 
(DTLET) > [D-Serz, LeuS] enkephalyl-Thr6 (DSLET). Saturation experiments performed with [3H]DPDPE 
and [3H]DTLET in NGl08-15 cells and rat brain showed similar binding capacities for both the ligands, 
but the &affinity of [3H]DTLET (I& z 1.2 nM) was much better than that of [3H]DPDPE (Ko z 7.2 nM). 
The rather low &afftnity of DPDPE induced high experimental errors cancelling the benefit of its better 
&selectivity. Binding experiments in rat or guinea-pig brains showed, in both cases, the better &selectivity 
of [3H]DTLET compared to [3H]DSLET. The former peptide remains at this time the most appropriate 
radioactive probe for binding studies of a-receptor. 
&Enkephalin analogue Opioid receptor binding 
1. INTRODUCTION 
Considerable interest has been devoted to the 
biochemical and pharmacological properties of the 
6 opioid receptor type [I]. However, the lack of 
fully S-selective ligands has led to controversy [2] 
about its molecular nature, i.e., whether it is an in- 
dependent receptor [3,4] or p-interconvertible con- 
formation [5] or allosteric site [6,7]. From both ex- 
tensive conformational studies performed by NMR 
and theoretical calculations, FourniC-Zaluski et al. 
[8] proposed structural requirements for ligands to 
preferentially interact with p or 6 sites. This led to 
Abbreviations: DAGO, [D-Ala2,(Me)Phe4,Gly-o15]- 
enkephalin; DADLE, [D-Ala*,D-Leu’lenkephalin; 
DSLET, [D-Ser2,Leu5]enkephalyl-Th?; DTLET, [D- 
Thr’,Leu’]enkephalyl-Thr6; DPDPE, [D-Pen*,D-Pen’]- 
enkephalin; DPLPE, ID-Pen*,L-Pen’lenkephalin 
Rat brain Guinea-pig brain NG108-15 hybrid cell 
the syntheses of Tyr-D-Ser-Gly-Phe-Leu-Thr 
(DSLET) and Tyr-D-Thr-Gly-Phe-Leu-Thr 
(DTLET), which have also been in tritiated form 
[9, lo]. Owing to their enhanced -selectivity, these 
ligands have therefore been used, in preference to 
the poorly selective [D-Ala2,D-Leu’lenkephalin 
[lo], to elucidate the pharmacological role of the 6- 
receptor [I l-151, its distribution in the rat brain 
[16] and its binding properties [ 171. Recently, 
Mosberg et al. [18] described two conforma- 
tionally restI;icted cyclic enkephalin analogues, 
[D-Pen2,D-Per?]enkephalin (DPDPE) and 
[D-Pkn2,L-P&]enkephalin (DPLPE), which show 
an even better selectivity for the b-binding site than 
the linear peptides DSLET and DTLET. All of 
these analogues exhibit very low potencies at x 
sites [22]. As one of the cyclic compounds, 
[3H]DPDPE, is now commercially available, it was 
of interest to study its binding properties on rat 
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brain tissue which contains both ,U and 6 receptor 
types, with the aim of performing competition ex- 
periments with selective p-agonists. 
tration of the labelled ligand and KD its 
equilibrium dissociation constant. Linear regres- 
sion analyses were done on a Hewlett-Packard 
HP85A desk calculator. 
2. MATERIALS AND METHODS 
2.1. Chemicals 3. RESULTS 
DSLET [ 191 and DTLET [lo] were prepared as 
previously described. DPDPE and DPLPE were a 
generous gift from Dr H.I. Mosberg or purchased 
from Bachem, AG. t3H]DTLET (45 Ci/mmol) 
was obtained from its 2,5-dibromotyrosyl precur- 
sor [20]. [3H]DSLET (30.5 Ci/mmol) was purchas- 
ed from New England Nuclear and [3H]DAG0 
(60 Ci/mmol) and [3H]DPDPE (35 Ci/mmol) 
from Amersham. 
3.1. Selectivities of bis-penicillamine enkephalins 
Selectivities of linear and cyclic enkephalin 
analogues for p and 6 sites of rat brain were in- 
directly determined by inhibition experiments us- 
ing [3H]DAG0 (1 nM), a p-selective ligand [21] 
and t3H]DSLET (2 nM), a nearly &selective ligand 
[9, lo] (table 1). The Hill coefficients accounted for 
the homogeneity of the displacement curves 
observed. 
2.2. Preparation of crude membrane fractions and 
binding assays 
The experiments were performed on male 
Sprague-Dawley rats and guinea-pigs (Ruvel, 
France). NG10815 cells were cultivated in Dulbec- 
co’s modified Eagle’s medium. Crude membrane 
preparations and binding assays were previously 
described [ 171. NG 108- 15 cells were homogenized 
with a Polytron grinder, prior to centrifugation at 
100000 x g for 35 min. All binding assays were 
carried out in triplicate in a volume of 1 ml, at 
35°C for 45 min unless otherwise indicated. 
The KI values were calculated from the relation- 
ship Kr = IC&(l + L/J&) where L is the concen- 
As shown in table 1, bis-penicillamine 
enkephalins DPDPE and DPLPE had higher Kr 
values at the p-binding site than DSLET and 
DTLET. However, in agreement with a previous 
study [18], the conformationally restricted 
enkephalin analogues showed weaker inhibition 
potencies at S-sites than the more flexible linear 
peptides. As illustrated by the ratio of their respec- 
tive KI values for 6 and/l sites, the selectivity of the 
studied peptides (table 1) increased over the 
following range: DSLET, DTLET, DPDPE, 
DPLPE. These findings disagree with other papers 
[4,18,22] reporting a better selectivity for DSLET 
than DTLET. 
Table 1 
Inhibitory potencies of enkephalin analogues on the binding of (3H]DAG0 (1 nM) at p-site and of 13H]DSLET (2 nM) 
at d-site in rat brain tissue 
Analogues 
(%) 
p-site J-site K&W 
K&u) 
n Hill” 
(Z) 
n HW’ 
DPLPE 873 f 210 0.83 f 0.09 (4) 10.9 + 1.2 0.85 + 0.05 (5) 0.0125 
DPDPE 993 f 151 0.80 + 0.03 (3) 19.2 + 1.4 0.82 f 0.05 (4) 0.0193 
DTLETb 25.3 + 2.5 0.85 + 0.03 (5) 1.35 I!z 0.15 0.86 f 0.02 (5) 0.053 
DSLETb 31.0 * 5.0 0.80 f 0.05 (4) 4.80 + 0.80 0.81 + 0.04 (4) 0.15 
a Means t SE 
b Values from [lo] 
Results were obtained at 35°C from the analysis of Hill plots using 8 concentrations of unlabelled compound. The 
number of observations is given in parentheses 
440 
Volume 183, number 2 FEBS LETTERS April 1985 
While DPDPE was approx. 2.5times more 6- 
selective than DTLET, the latter displayed a 
ll-times higher apparent affinity for the S receptor 
type. 
3.2. Binding characteristics of [3n]DPDPE and 
pH]DTLET on rat brain and NGlO&15 cells 
membranes 
In the case of [3H]DPDPE (10 nM), steady-state 
conditions were established from association 
kinetics on rat brain membranes at 35 and 4°C. 
Equilibrium was reached in 45 min at 35°C 
(k+i(app) = 0.061 min-‘) and in 2 h at 4°C 
(k+i(app) = 0.020 min-‘). However, the specific 
binding at 4°C was only 51% of that at 35°C. The 
binding kinetics of [3H]DTLET have already been 
determined [lo]. 
Saturation experiments were performed on 
membranes from rat brain and NGlOS-15 cells, at 
35°C. The equilibrium dissociation constants (KD) 
and binding capacities (Bmax) were calculated from 
linear regression analysis of the saturation 
isotherms by either Scatchard or Eadie-Hofstee 
plots. The accuracy in the determination of bind- 
ing parameters can be evaluated from the standard 
deviation of the error of the raw data, SD(Erad) 
[23]. As shown in table 2, in rat brain the SD(Erad) 
for [3H]DTLET was around 5% while it reached 
20% for [3H]DPDPE. The range of error for the 
two radioligands is illustrated in fig.1 by the dif- 
ferences in Bmax and KD values derived from least- 
squares linear regression analyses of Scatchard and 
Eadie-Hofstee plots [24]. Since the specific binding 
of [3H]DPDPE was greater in NGlOS-15 cells, its 
KD values derived from the two analyses were 
similar, leading therefore to an accurate SD(Erad) 
estimate of 5%. As shown in table 2, [3H]DPDPE 
had one sixth of [‘HIDTLET affinity. The binding 
capacity of [3H]DPDPE in rat brain showed no 
significant difference from [3H]DTLET binding 
capacity. 
3.3. Binding of fH]DSLET and tH]DTLET in 
rat and guinea-pig brains 
Saturation experiments of [3H]DSLET and 
[3H]DTLET showed that in both preparations 
[‘HIDTLET exhibited the highest affinity: KJJ = 
1.36 + 0.12 nM against 3.49 + 0.22 nM for 
[3H]DSLET in rat brain and KD = 1.08 + 0.08 nM 
against 1.97 k 0.16 nM for [3H]DSLET in guinea- 
pig brain. In accordance with its higher cross- 
reactivity, the capacity for [3H]DSLET was 29% 
greater than for [3H]DTLET in rat brain (141 + 9 
and 109 f 7 fmol/mg, respectively) and 23% 
greater in guinea-pig brain (86 -t 6 and 70 + 
5 fmol/mg, respectively). This higher cross- 
reactivity of [‘HJDSLET agrees with a recent 
report [22] and is in accordance with competition 
studies [ 10). 
Table 2 
Binding parameters of [‘HIDPDPE and [3H]DTLET in crude membrane fractions of rat brain and NG108-15 cells at 
35°C 
‘H-labelled 
ligand (nM)b 
Tissue Scatchard analysis 
a 
(zf , B a ( fm;Ymg) 
Eadie-Hofstee analysis 
B a 
(fmcYKmg) 
SD(Erad)” 
(%) 
DPDPE (I-20) Rat brain 10.5 f 2.4 118 f 11 5.68 f 0.63 86* 3 20.0 i 2.9 (4) 
NG108-15 7.28 + 0.05 419 + 13 7.10 f 0.14 410 f 11 5.2 f 1.3 (3) 
DTLET (0.5-7) Rat brain 1.19 * 0.14 103& 5 1.12 f 0.12 101 f 4 5.1 f 1.2 (4) 
NG108-15 1.25 + 0.09 430 f 10 1.19 f 0.08 419 f 9 4.7 f 1.1 (3) 
a Means f SE 
b Concentration range of tritiated ligand used (6 concentrations in a volume assay of 0.5 ml) 
The number of observations i  given in parentheses 
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B , pmohvmg 
6. mcde~mg nhi 
Fig. 1. Scatchard (solid lines) and Eadie-Hofstee (dotted 
lines) analyses of [3H]DTLET (m) and f3H]DPDPE (0) 
specific binding: results from one experiment performed 
on the same homogenate of rat brain (upper plots) or 
NG108-15 cells (lower plots). In the Scatchard 
representation, B/F is plotted as a function of B (B/F = 
B,JKD - (l/Kn)*B); in the Eadie-Hofstee 
representation, B is plotted as a function of B/F (B = 
B max - KD*(B/F)) (inverted axes). Thus, the 
independent variables are, respectively, B and B/F. The 
corresponding saturation curves are shown on the right 
side. The concentration ranges were 25-84 and 9-67% 
of saturation for [3H]DTLET and [3H]DPDPE, 
respectively. 
4. DISCUSSION 
Two main molecular approaches for designing S- 
probes were successfully used by FourniC-Zaluski 
et al. [S] and Mosberg et al. [ZS]. The highly con- 
formation~ly restricted enkephalin analogues 
DPDPE and DPLPE exhibit an enhanced 6- 
selectivity but unfortunately this is associated with 
a large decrease in affinity. This could indicate that 
the loss of flexibility may not be favourable for the 
transconformational binding process [26]. The low 
specific binding of [3H]DPDPE, 26% at 67% 
saturation, led to large standard deviations com- 
pared to 13H]DTLET which displayed 79% specific 
binding at 43% saturation. The use of low 
temperature (4°C) does not improve the specific 
binding of the cyclic peptide. These features pro- 
bably account for the large difference observed 
between the KD and Kt values for DPDPE while 
these parameters were almost identical for 
DTLET. Therefore, 13H]DPDPE cannot be safely 
used, either for competition studies or for acute 
determinations of the concentration of 6 sites in 
brain following biochemical lesions or phar- 
macological manipulations. 
In conclusion, t3~]DTLET seems to be the most 
appropriate radioligand for binding studies and 
the cyclic analogue should be reserved for phar- 
macological experiments. 
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